FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Unity Biotechnology, Inc. Stock AnalysisComprehensive stock analysis for Unity Biotechnology, Inc. (UBX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisUBX
UBX
Unity Biotechnology, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
UBX
Home🔹Stocks🔹Unity Biotechnology, Inc.

Unity Biotechnology, Inc.

UBX•NASDAQ

Unity Biotechnology, Inc.

UBX•NASDAQ
Market cap
$3.44M
Sentiment

Your view on UBX

Mkt Cap
$3.44M
Sentiment
Your view
UBX
Unity Biotechnology, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
UBX
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Unity Biotechnology, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Anirvan Ghosh
Headquarters
285 East Grand Avenue, South San Francisco, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Anirvan Ghosh
Headquarters
285 East Grand Avenue, South San Francisco, CA, US
Description

Unity Biotechnology, Inc. is a biotechnology firm specializing in the development of therapeutic solutions aimed at slowing, halting, or even reversing age-associated diseases. Leading its pipeline, the drug candidate UBX1325 is currently undergoing Phase II clinical trials to treat age-related vision disorders, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. Additionally, the company is advancing UBX1967 for various ophthalmologic conditions, while UBX2050, a human anti-Tie2 agonist monoclonal antibody, also targets age-related eye diseases. Furthermore, UBX2089, an a-Klotho hormone drug candidate, is in development for numerous neurological indications. Established in 2009 as Forge, Inc., the company adopted the name Unity Biotechnology, Inc. in January 2015 and is headquartered in South San Francisco, California.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

FRC's fair value estimate for Unity Biotechnology, Inc., and the rating behind it. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Unity Biotechnology, Inc.. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Unity Biotechnology, Inc.. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Unity Biotechnology, Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Unity Biotechnology, Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Unity Biotechnology, Inc. valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Which institutions hold Unity Biotechnology, Inc., and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

Buying and selling by Unity Biotechnology, Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Unity Biotechnology, Inc.. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Unity Biotechnology, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Unity Biotechnology, Inc.. Press releases and market coverage, newest first.

News

Latest Market News